January 13, 2021
2 min read
Disclosures: Kalincik reports receiving advisory board or steering committee fees, research and/or conference travel support and speaker honoraria from BioCSL, Biogen, Genzyme-Sanofi, Merck/EMD, Novartis, Roche, Teva and WebMD. Please see the study for all other authors’ relevant financial disclosures.
Back to Healio
Long-term exposure to immunotherapy reduced the rate of relapses and disability progression among a large cohort of patients with MS followed for 15 years, according to findings published in Neurology.
“A proof of long-term effect of immunomodulation on the accumulation of MS-related neurological disability is the key to establishing its disease modifying properties,” Tomas Kalincik, MD, PhD, a principal research fellow in neurological outcomes at Royal Melbourne Hospital, and colleagues wrote. “Here we present a study from the largest international MS registry, whose aim was to compare worsening and improvement of disability and incidence of relapses during periods of treatment vs. no treatment with MS immunotherapies over more than 15 years of follow-up.”
Kalincik and colleagues conducted a case control study of patients with MS who were exposed to immunotherapy and had follow-up data of at least 1 year.…